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Abstract 
An ideal test used to characterize a product must be appropriate for the 
measurement of product quality, manufacturing consistency, product stability, 
and comparability studies. Flow cytometry has been successfully applied to the 
examination of antibodies and receptors on membrane surfaces; however, to 
date, the analytical validation of cytometry based assays is limited. Here we 
report on the validation of a flow cytometry-based assay used in the evaluation 
of  nimotuzumab binding to cells over-expressing EGFR on cell surface. The 
assay was validated by examining, assay robustness, specificity, repeatability 
and intermediate precision. The assay was highly specific, robust for all studied 
factors except for cell fixation with 1% paraformaldehyde and met criteria for 
precision with RSD < 2%. In addition the assay has stability-indicating proper-
ties evidenced by the ability to detect changes in mAb degraded samples. Most 
importantly, the assay demonstrated to be useful for its intended use. 
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Introduction 
Most biological products act through some form of binding to another moiety. 
Fluorescence flow cytometry is used in the observations and analysis of the interaction of 
fluorescently labeled ligands and their cellular receptors. Binding assay by flow cytometry 570  M. Cedeño-Arias et al.:   
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is commonly used to characterize the activity of the product through binding to its specific 
receptor. When the mechanism of action of a monoclonal antibody (mAb) is to block the 
binding of ligand to cell surface receptor, in vitro binding assay can be used as surrogate 
potency test using the therapeutic mAb [1]. 
The development of accurate and well characterized assays for biological products is vital 
for their development as therapeutic drug [2]. The biological activity measured should be 
closely related to the product's intended biological effect and ideally it should be related to 
expected clinical response [3, 4].  
Nimotuzumab (also known as h-R3) is an IgG1 humanized anti–epidermal growth factor 
receptor (EGFR) mAb that was obtained by complementarity determining regions grafting 
of a murine mAb to a human framework [5]. Nimotuzumab binds to domain III of the 
extracellular region of the EGFR and interferes with EGF binding [5, 6]. At present, 
nimotuzumab is one of the very few anti-EGFR monoclonal antibodies that have been 
approved for therapeutic use in cancer treatment. 
The appropriate validation of any bioassay used in the characterization of biological 
products is critical. Regulatory agencies provide general guidance on validation of 
analytical methods [3, 4] although these are not specific to biological assays. Validation of 
a cell-based bioassay [7], and immunoassays for bioanalysis has been reviewed [8], 
however very few information is available for validation of flow cytometry assays [9].  
Here, we report on the validation study (assay robustness, specificity and precision) of the 
nimotuzumab binding assay by Flow Cytometry.  
Results and Discussion 
The validation of analytical procedures is an important part in the registration application 
for a new drug [2]. Based on the method characteristics and requirements of the 
International Conference on Harmonization  (ICH) guidelines, each analytical procedure 
must be validated with respect to parameters which are relevant to its performance [8, 10]. 
Reagent titration 
Cytometry can measure both phenotypic and functional parameters from cells and has 
been used in the diagnosis and monitoring of progression of diseases and also to 
demonstrate biological activity of drugs [9]. In order to determine the optimum 
concentration of nimotuzumab used in the assay the reagent was titrated on two epithelial 
cell line over-expressing EGFR and a titration curve was created. A typical standard curve 
is shown in figure 1. For the data shown in figure 1a, saturation of binding was achieved at 
a concentration of 3–5 µg/mL of nimotuzumab when % of binding was reported. While 
mean of fluorescence intensity (MFI) was examined (Figure 1b), the saturating mAb 
concentration was of 10–20 µg/mL in both cell lines. As reported before, A 431 showed a 
higher antigen density [11] on cell surface than NCI-H125 cell line [12]. In the subsequent 
experiments we always used the parameter % of binding for the analysis because 
demonstrate less variability of the results when the assay is performed multiple times 
(RSD less than 1% at 3 µg/mL of mAb). However, when MFI was measured the inter-
assay variability shown RSD higher than 10%.   Validation of a Flow Cytometry Based Binding Assay for Evaluation of Monoclonal Antibody …  571 
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Fig. 1.   A typical dose-response curve for a FACS-binding assay data set is shown. 
Graph in (A) shows % of binding and in (B) mean of fluorescence intensity of 
nimotuzumab on cell surface EGFR in two different tumor cell lines. 
Assay robustness  
Robustness testing is part of method validation [3, 13]. Especially in the pharmaceutical 
industry, extensive method validation is required in order to meet the regulations set by the 
regulatory agencies. For robustness study the factors selected have to reflect potential 
changes that may occur during validation process. 
The robustness of the assay was performed also on two cell lines. Ten factors were 
selected from the analytical procedure to be examined. As shown in table 1 in this study 
qualitative and quantitative factors were evaluated. The factors were investigated in a 
Plackett-Burman design and the levels for each factor used are given in tables 1 and 2. In 
each of the 12 experiments performed, the average from three replicates of % of binding is 
shown in table 1. The statistical analysis described above and the results are given in 
Table 2 and plotted in figure 2.  572  M. Cedeño-Arias et al.:   
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Tab. 1.   Plackett-Burman design for 11 factors. % of nimotuzumab binding in both A 431 
and NCI-H125 cell lines. 
  Factor  % of Binding 
Exp.  A  B  C  D  E  F*  G  H  I  J  K  A431  H125 
1  +  +  −  +  +  +  −  −  −  +  −  99,73  99,73 
2  −  +  +  −  +  +  +  −  −  −  +  98,73  97,80 
3  +  −  +  +  −  +  +  +  −  −  −  99,23  98,70 
4  −  +  −  +  +  −  +  +  +  −  −  99,23  99,47 
5  −  −  +  −  +  +  −  +  +  +  −  99,73  99,93 
6  −  −  −  +  −  +  +  −  +  +  +  99,83  100,00 
7  +  −  −  −  +  −  +  +  −  +  +  99,57  99,70 
8  +  +  −  −  −  +  −  +  +  −  +  99,60  98,13 
9  +  +  +  −  −  −  +  −  +  +  −  99,87  99,37 
10  −  +  +  +  −  −  −  +  −  +  +  99,83  100,00 
11  +  −  +  +  +  −  −  −  +  −  +  99,87  98,20 
12  −  −  −  −  −  −  −  −  −  −  −  97,73  98,43 
Average                        99,41  99,12 
RSD                        0,63  0,82 
Exp…No of experiments; +…High level; −…Low level; *…Dummy factor. 
 
Tab. 2.   Effects of factors on the response of % of binding of nimotuzumab on cells lines 
over-expressed EGFR measured by Flow cytometry. 
  Effects 
Factors  A 431  NCI-H125 
Cell Culture Media manufacturer  −0,005  0,103 
Fetal Bovine Sera manufacturer  0,129  0,245 
Time of Trypsinization  0,551  0,123 
Trypsin-EDTA manufacturer  0,171  −0,077 
Incubation time for EGFR recovery  0,465  −0,300 
Incubation time of mAb  0,261  −0,243 
Incubation time of FITC-conjugated  0,239  0,4 
Volume of mAb  0,415  0,457 
Volume of FITC-conjugated  0,319  −0,301 
Formaldehyde cell fixation   0,695
a  1,333
a,b 
Dummy Factor   0,125  −0,152 
Mean of modular values of effects  0,261  0,245 
Experimental error estimated according algorithm of Dong 
s0  0,3915  0,3675 
2,5x s0  0,97875  0,91875 
s1  0,36477  0,26894 
ME (α=0,05)  0,803  0,599 
ME (α=0,1)  0,655  0,487 
a Significant at α=0,1; 
b Significant at α=0,05; s0= Estimate of error; s1=Standard errror; ME 
=margin of error. 
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Only the cell fixation with 1% formaldehyde (factor J) represents a significant factor 
affecting the response in both cell lines at α=0.1. After formaldehyde fixation cells showed 
a higher % of mAb binding and in MFI probably due to gain in surface marker detection in 
a subset of cells (above background level) most evident in NCI-H125 cell (significant also 
at α=0.05). The results found with the statistical and graphical interpretation agreed.  
Several investigators have used prefixed cells for analysis by flow cytometry. The most 
widely used compound is paraformaldehyde, generally in a concentration of 1 or 2% prior 
to antibody staining. Fixing samples with formaldehyde increases cell permeability and 
causes surface protein cross-linking that may alter staining of both intra- and extracellular 
markers [14]. The time of fixation varies from several minutes to overnight. Both over and 
under-fixation usually results in a loss of antigenicity. The reason for the increase in 
fluorescence, though, is not clearly understood. Studies that have examined fixation on 
sample preparation have produced contradictory results. 
 
Fig. 2.   Half-normal probability plot for the effects estimated in Plackett-Burman design 
(from Table 2) with the identification of margin of error (ME). Variable: % of 
binding of nimotuzumab evaluated by flow cytometry on A 431 (A) and H125 (B) 
cell lines respectively. 
Specificity 
Assay specificity is an important and critical issue. The nonspecificity results from the 
interferences of compounds with similar physicochemical properties to those of the analyte 
and it is sometimes referred as the matrix effect [15]. The specificity of the assay was 
evaluated to assure mAb binding to antigen on cell surface. As we expected, low 
background binding was observed from samples with no mAb (< 5% for isotype T1hT 
irrelevant mAb and different mAb-free matrix solutions). While, nimotuzumab is bound 
specifically to cell surface (≥ 97 %) in the relevant samples containing mAb (reference 
standard and mAb in culture supernatant).  
Although the high percentage of binding of degraded (pH adjusted to 10 and incubated at 
40°C for 168 hours) sample of mAb was evidenced, the result was lower than with non-
degraded molecule (Table 3).  
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Tab. 3.   Specificity data for nimotuzumab binding assay. 
Samples 
% of Binding 
(Average) 
Acceptance 
criteria 
(%)  A 431  NCI-H125 
Isotype mAb  T1hT  3,07  0,87  < 5,00 
Matrix  Formulation solution  1,97  0,50  < 5,00 
Culture supernatant  1,37  0,83  < 5,00 
Nimotuzumab 
Reference standard  99,93  99,97  ≥ 97,00 
Culture supernatant  99,97  100  ≥ 97,00 
Degraded sample  92,77  67,93  < 97,00 
 
To evaluate the occupation of EGFR by degraded mAb, a competition assay was 
performed and the inhibition of binding of FITC-conjugated nimotuzumab exerted by the 
degraded isotype control, native and degraded nimotuzumab was measured (Fig. 3).  
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Fig. 3.   Binding of nimotuzumab to EGFR expressed on A431 cell line. The graphs 
represent a comparison between native and degraded-mAbs. [A], % of binding 
and [B], mean intensity of fluoresce of degraded isotype control (□), degraded 
nimotuzumab (○), native nimotuzumab (●), or native FITC-conjugated 
nimotuzumab (●), antihuman/FITC was used as secondary Ab when non-
conjugated mAb was evaluated. [C], Results of competition binding assay, 
concentrations from 0.01 to 50 µg/mL of native and degraded mAbs were 
incubated for 30 min at 4°C in the presence of FITC-Conjugate nimotuzumab 
(2.5 µg/mL). 
Native mAb showed a higher degree of receptor occupation than degraded mAb. In 
contrast degraded isotype negative control showed no bound to the receptor (Fig. 3A-B). 
Increasing concentration of native mAb may be more effective than degraded in 
displacement the labeled antibody (Fig. 3C). This result probably due to the native 
conformation of mAb was destroyed during degradation process with lost biological mAb 
activity or it is not sufficient to make action. To confirm that mAb was maximally degraded, 
the electrophoretic procedures (SDS-PAGE and isoelectric focusing) were used (data no 
shown). The concentrations at which 50% effect occurred were 6.01 and 30.7 µg/mL for 
native and degraded mAb respectively.    Validation of a Flow Cytometry Based Binding Assay for Evaluation of Monoclonal Antibody …  575 
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Precision (repeatability/reproducibility) 
Precision is a measure of the ability of the method to generate reproducible results [3, 4]. 
The precision of assay was evaluated using three separated determinations with two cell 
lines for repeatability (intra-assay) and intermediate precision (inter-day and inter-person 
variability).  In order to calculate the assay precision, the average, SD and RSD were 
determined from the six replicates determined on individual days. Representative data is 
shown in table 4.  
Tab. 4.   Precision results.  
Average, Standard Deviation and RSD of six replicates over 3 days. 
Cell Line  A 431  NCI-H125 
Average  SD  RSD  Average  SD  RSD 
Intra assay 
A
n
a
l
y
s
t
 
1
  Day 1  FP  99,68  0,16  0,16  99,85  0,08  0,08 
CS  99,48  0,30  0,30  99,83  0,23  0,23 
Day 2  FP  99,40  0,39  0,40  99,58  0,08  0,08 
CS  99,70  0,17  0,17  99,78  0,12  0,12 
Day 3  FP  99,25  0,38  0,38  99,52  0,29  0,29 
CS  99,65  0,10  0,11  99,53  0,47  0,47 
A
n
a
l
y
s
t
 
2
  Day 1  FP  98,62  0,84  0,85  99,28  1,03  1,04 
CS  99,43  0,25  0,25  99,15  1,41  1,43 
Day 2  FP  98,30  0,72  0,73  99,97  0,05  0,05 
CS  99,65  0,19  0,19  99,95  0,08  0,08 
Day 3  FP  99,45  0,39  0,40  99,23  0,82  0,83 
CS  99,77  0,19  0,19  98,85  1,64  1,66 
Inter assay 
Analyst 1  FP  99,44  0,36  0,36  99,65  0,22  0,22 
CS  99,61  0,22  0,22  99,73  0,33  0,33 
Analyst 2  FP  98,79  0,81  0,82  99,49  0,79  0,80 
CS  99,62  0,24  0,24  99,32  1,27  1,28 
Inter analyst 
2 Analysts  FP  99,12  0,70  0,71  99,57  0,58  0,58 
CS  99,61  0,23  0,23  99,53  0,94  0,94 
Data is shown as % of binding (Average, SD and RSD). Nimotuzumab is evaluated as purified final product 
(FP) and culture supernatant (CS). 
 
Intra assay precision expresses the precision under the same operating conditions (during 
a single analytical run). For intra assay precision, two analyst tested samples in three 
repeats for both NCI-H125 and A431 cell lines using nimotuzumab as culture supernatant 
or as purified mAb. Average % of binding (N=6 each) were found ≥ 98%.  
RSD [(intra assay SD/Intra assay average calculated value) x 100] was < 2% which is 
considered acceptable.  
Inter assay precision (Intermediate precision) is defined as the variability of a sample 
tested in multiple assays over than one day. The data are expressed as average value and 576  M. Cedeño-Arias et al.:   
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RSD [(inter assay SD/Inter assay average calculated value) x 100]. Inter assay precision 
was also assessed by two analysts in three independent assays. Similarly, average 
(N=18) was also satisfactory with RSD < 2%. This degree of precision compares well to 
reported for binding assays with RSD between 5–20% is considered acceptable [16]. 
Usually acceptable repeatability of the results within one day  and day-to-day was 
observed. The result obtained from inter-person reproducibility (N=36) is <1%, also 
indicated a good method precision. Assay precision for flow cytometry binding assay met 
the general criteria with RSD <20% (intra assay) and < 25% (inter assay) [8]. 
Experimental 
Antibodies and sample preparations 
Nimotuzumab  (mAb-containing sample) as culture supernatant, the internal reference 
standard and other two purified lots were used. As mAb-free matrix sample, a batch of 
buffer solution used in drug formulation and complete cell culture media were used. T1hT 
(IgG1, anti CD6 mAb at 5 mg/mL) manufactured by Biocon, India was used as isotype 
control. Degraded sample of both, nimotuzumab and T1hT mAbs, were prepared by pH 
adjusted to 10 with 1M NaOH and incubated at 40°C for 168 hours). All mAbs were kept at 
2-8°C until use.  
All working dilutions of samples were obtained by diluting the stock solution (5.0 mg/mL) 
with FACSflow, first at 50.0 µg/mL and further diluting to final concentrations. All samples 
were prepared daily prior to assay.  
In robustness assays reagents from two different brands were used, Gibco-BRL, USA and 
PAA, Austria: Dulbecco’s Modified Eagle Medium (DMEM) from Gibco (12800-017) and 
PAA (E15843). Fetal bovine serum (FBS) from Gibco (10082) and PAA (A 15-211). 0.25% 
Trypsin–EDTA from Gibco (25200-056) and PAA (L11-660). 1% formaldehyde (Sigma-
Aldrich, USA) prepared in FACSflow solution (BD 342003, USA) was used for cell fixation. 
FITC conjugation of Nimotuzumab  
Nimotuzumab was conjugated with reactive fluorescein isothiocyanate (FITC) according 
[17] with minor deviation. Briefly, 7.5 mg (1.5 mL) of mAb was exchange over a Hitrap 
Desalting column from General Electric (17-140801) in reaction buffer (500 mM carbonate, 
pH 9.5). Covalent conjugation was made wrapped in foil and incubated for 1.5 h with 
gentle rotation at room temperature. Unreacted FITC was removed and the antibody was 
exchanged into storage buffer (PBS, pH 7.4).  
Cell line and culture conditions 
The human epidermoid carcinoma cell line A431 (CRL-1555) and non small lung cell 
carcinoma NCI-H125 (CRL-5801) were obtained from the American Type Culture 
Collection (ATCC, Rockville, MD). Cells were cultured in DMEM (Gibco, USA) 
supplemented with 5% and 10% respectively of FBS  (Gibco, USA) under standard 
conditions (37°C in humidified atmosphere containing 5% CO2). Cells were used around 
90% of confluence at time of assay, detached with 1 mL of Trypsin-EDTA for 10 min 
(A431) and 5 min (NCI-H125) respectively and then resuspended in complete growth   Validation of a Flow Cytometry Based Binding Assay for Evaluation of Monoclonal Antibody …  577 
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medium.  Cell concentration and viability were determined with a hemacytometer  using 
Trypan-blue exclusion method. 
Surface binding mAb analysis 
Cells were resuspended in complete culture medium and kept in a water bath at 37°C for 
60 min. Cell concentration was adjusted at 1x10
6 cells/mL and the staining was performed 
in 2.5 x10
5 cells. The mAbs were added according to the experimental plan, and cells were 
stained for 30 min at 2–8°C. The cells were washed with 2 mL of FACS flow and spin out 
at 246 g for 10 min at 4°C. FITC-conjugated rabbit anti human IgG (Dako F0056, 
Denmark, 1:60) was added and cells were stained for 30 min at 2–8°C. Cells were washed 
as described before and resuspended in 200 µL of FACSflow for flow cytometric analysis. 
In robustness analysis, cells were resuspended in 200 µL of 1% formaldehyde and 
incubated for 24 hours at 2–8°C before flow cytometric analysis. A Becton Dickinson 
FACSCan instrument using 488 argon lasers was used.  
Assay validation  
Robustness  
Assay robustness was defined as how "reproducibly" the assay performed over time after 
deliberate manipulation of environmental parameters. A Plackett-Burman [13] design for 
11 factors (N=12) was performed to investigate the influence of certain experimental an 
environmental factors on assay outcome (Table 5). For each factor, the nominal level was 
considered as in a regular assay (see in table 5 and described before in surface binding 
mAb analysis) and the extreme level (− or +) was considered as a level deviation from the 
nominal one. All experiments were performed in randomized order and carried out in short 
space of time in four experimental blocks including three experiments each: B-I 
(experiments 1, 5 and 11); B-II (experiments 2, 4 and 7); B-III (experiments 3, 6 and 9) and 
B-IV (experiments 8, 10 and 12).  
Specificity 
The specificity of the assay is the ability of the assay to measure the analyte unequivocally 
in the presence of other components in the sample. Here we evaluated the matrix 
interference (excipients used in culture supernatant and in final buffer formulation), 
irrelevant mAb (isotype control), positive sample (nimotuzumab in culture supernatant and 
formulated as final product, including an internal references standard) and degraded 
sample. 
Precision (repeatability/reproducibility) 
Assay precision was determined evaluating internal references standard, and 
nimotuzumab (in culture supernatant and purified as a final product) at 3 different times. 
Each run of the assay was performed on three separated occasions. Assay was assessed 
by six replicates of the drug over time within the same day (intra- assay repeatability) and 
on three different days (inter-day variation), and across individuals (inter-person 
reproducibility). In order to calculate the assay precision, the average, standard deviation 
(SD) and relative standard deviation (RSD) as [(SD/average) x 100] were determined. 
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Tab. 5.   Factors and levels evaluated in the robustness assays. 
Factor  ID  Factor  
classific.  Limit  Low Level 
(-) 
High 
Level 
(+) 
Nominal 
Level 
Cell Culture Media 
manufacturer  G  qual.  –  GIBCO  PAA  GIBCO 
Fetal Bovine Sera 
manufacturer   E  qual.  –  GIBCO  PAA  GIBCO 
Time of Trypsinization  I  quant.  ±1 min 
11 min 
(A431) 
13 min 
(A431) 
12 min 
(A431) 
2 min 
(H125) 
4 min 
(H125) 
3 min 
(H125) 
Trypsin-EDTA 
manufacturer  B  qual.  –  GIBCO  PAA  GIBCO 
Incubation time for EGFR 
recovery   A  quant.  ±10 min  50 min  70 min  60 min 
Incubation time of mAb  C  quant.  ±5 min  25 min  35 min  30 min 
Incubation time of FITC-
conjugated  H  quant.  ±5 min  25 min  35 min  30 min 
Volume of mAb   D  quant.  ±5 µL  15 µL  25 µL  20 µL 
Volume of FITC-
conjugated  K  quant.  ±5 µL  15 µL  25 µL  20 µL 
Formaldehyde cell fixation   J  qual.  –  No  Yes  No 
 
Stability  
The suitability of FACS assay to be stability-indicative of nimotuzumab was determined by 
a competition binding immunoassay. Increasing concentrations of mAbs (native and 
degraded samples) were added to cell suspension in the presence of a constant amount 
(2.5  µg/mL) of FITC-conjugated native mAb. The assay was performed as described 
previously in surface binding mAb analysis. The % of binding and median of fluorescence 
intensity (MFI) curves generated from the results of duplicate were averaged. The 50% of 
response was also determined using GraphPad Prism program.  
Data analysis  
After acquisition, all raw data were analyzed using WinMDI 2.8 (free Software 
http://facs.scripps.edu/software.html). Percent of nimotuzumab  positive cells were 
obtained from upper right quadrant of cell gated in forward and side scatter profile. Median 
of fluorescence intensity (MFI) value was determined for positive population of cells.  
In robustness assay, statistical and graphical analyses of the effects were performed for 
interpretation. Algorithm of Dong [13] was used to identify significant effects and a half-
normal probability plots were drawn to indicate visually relevant effects. The average, SD, 
standard error and RSD were calculated using Excel 2007 (Microsoft). 
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Overall criteria for evaluation 
Percent of positive cells of isotype mAb (T1hT) and placebo solutions should be not more 
than 5% of positive cells of internal reference standard and nimotuzumab samples should 
be more than 97%. Percent of nimotuzumab degraded sample should be less than 97%. 
RSD less than 3% was considered an acceptable parameter.  
Conclusion 
Development of a convenient, robust, specific and precise procedure is important in quality 
control laboratories. A simple and sensitive immunoassay  has been developed for the 
determination of nimotuzumab binding activity by flow cytometry. Validation was performed 
in accordance with the ICH guidelines and under current good manufacturing practices 
(cGMP). These studies confirm that flow cytometry is a useful and expeditious technique 
for detecting mAb binding on cell surface receptors maintains low assay variation. The 
assay showed a high level of specificity and was found to be free of interference through 
the validation process. Also the assay has stability-indicating properties as evidenced by 
the ability to detect changes in binding of mAb degraded samples.  
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